autologous anti-SLAMF7 CAR T cells

Autologous anti-SLAMF7 CAR T cells are an investigational cell therapy developed by the University Hospital of Würzburg (Universitätsklinikum Würzburg) for the treatment of multiple myeloma. These T cells are genetically modified using the non-viral Sleeping Beauty transposon system to express a chimeric antigen receptor (CAR) specific for Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7, also known as CS1 or CD319). SLAMF7 is a cell surface protein highly expressed on malignant plasma cells in multiple myeloma, as well as on natural killer cells and a subset of other immune cells. Upon infusion, these CAR-T cells recognize and bind to SLAMF7-positive myeloma cells, triggering T-cell activation, proliferation, and targeted cytotoxicity. The use of the Sleeping Beauty system is intended to simplify manufacturing and potentially improve the safety and efficacy profile compared to traditional viral vector-based CAR-T therapies. The therapy is currently being evaluated in the CARAMBA clinical trial (NCT04499339).

Other names

SLAMF7-directed CAR-T cellsSLAMF-7-directed CAR-T cellsSLAMF 7-directed CAR-T cellsCS1-directed CAR-T cellsCS-1-directed CAR-T cellsCS 1-directed CAR-T cellsanti-CS1 CAR-T cellsanti-CS-1 CAR-T cellsanti-CS 1 CAR-T cellsanti-SLAMF7 CAR-T cellsanti-SLAMF-7 CAR-T cellsanti-SLAMF 7 CAR-T cellsCD319-directed CAR-T cellsCD-319-directed CAR-T cellsCD 319-directed CAR-T cells